PRF will also be injected into problem areas to to increase collagen growth to help improve any specific problem areas
Side Effect Profile Gastrointestinal (GI) side effects, including nausea, vomiting, diarrhea, and constipation, are the most frequently reported issues with GLP-1 medications and are one of the top reasons people discontinue treatment
Glucagon Like Peptide-1 (GLP-1) Likes Alzheimers Disease
Lilly's massive R&D budget has also allowed it to focus on retatrutide, a so-called "triple-agonist" combining GLP-1 properties with other medications, that is currently in trial.
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: Post hoc analysis of the Irbesartan Diabetic Nephropathy Trial
The FDA and Novo Nordisk continue to monitor the situation and are working to stop the spread of unauthorized versions of the drug